MORGAN STANLEY

More in MORGAN STANLEY

• Varun Dhawan turns investor; invests undisclosed amount in start-up Fast&Up

  Bollywood actor Varun Dhawan invests an undisclosed amount in India’s leading active nutrition brand Fast&Up

  

• Fullife Healthcare receives US$22 mn funding from Morgan Stanley Private Equity Asia

  The investment will be instrumental in accelerating the growth of flagship brands Fast & Up and Chicnutrix

  

• Novavax expects to make available at least 2 bln COVID-19 vaccine doses in 2022

  Novavax, speaking at a Morgan Stanley healthcare conference, reiterated that it would have about 100 million doses per month by the end of the third quarter this year, and would increase it to 150 million doses in the fourth quarter.

  

• Diagnostics chain HealthMaP looks at merger with iGenetic

  iGenetic, co-founded by former senior executives of private equity firm Actis, is a leading specialised diagnostic chain that caters to the high-end critical care segment.

  

• H1N1 fears spread in India’s Silicon Valley

  A tech hub of Bengaluru was in the grip of an H1N1 influenza scare on Thursday after German software major SAP pressed the panic button following two of its employees in the city contracting the virus.

  

• Manipal-TPG in Rs 2k cr deal talks for Columbia Asia’s India assets

  Interestingly, TPG was part of the consortium — along with Malaysian conglomerate Hong Leong— that bought rest of the Asia operations of the Seattle-based chain. It paid $1.2 billion for 17 hospitals in Malaysia, Indonesia and Vietnam.

  

• Sun Pharma surges 3.6% after Morgan Stanley double upgrade

  Sun Pharma had plunged 41 per cent over the last two years in which the Sensex gained 31 per cent.

  

• Understanding the biosimilars opportunity for Indian pharma

  Several drugs classified as biologics are expected to go off patent during this period thereby making way for their biosimilar counterparts. Indian pharma companies active in this field are expected to be among the biggest beneficiaries of this opportunity.

  

• Nestle seeks to pip Unilever to grab GSK’s consumer nutrition business as Coca-Cola opts out

  GSK Consumer Healthcare shares have climbed about 10% this year, outperforming the Sensex gain of 3.6%, taking it to a market cap of Rs 30,249.29 crore.

  

• Global giants enter fray for GSK’s $4bn Horlicks unit

  GSK had announced a strategic review of its nutritional businesses in March this year, which could lead to a sale of its 72.5% stake in GSK Consumer Healthcare in India and similar operations in Bangladesh and a few other developing markets. The initial, non-binding offers were due on Monday.

  

• Kellogg, Reckitt Benckiser join queue for a glass of Horlicks

  Kellogg’s last big acquisition in India was Paras Pharmaceuticals eight years ago.